Can B7-33 Reduce Fibrosis?

Animal studies show that the B7-33 peptide can reduce fibrosis in damaged lung tissue. This research compound stops scarring at injury sites during wound healing. Researchers see how B7-33 blocks collagen production and inflammation.

The peptide changes how cells respond to tissue damage. Studies show benefits for conditions involving lung scarring and liver damage.

FOXO4-DRI peptide also helps reduce fibrosis by removing old cells. Both compounds show promise in lab tests for healing. Researchers use these peptides as research tools to study cellular processes.

Understanding why fibrosis worsens requires examining the harmful cells that fuel this process.

Explore B7-33 Peptide from Peptide Works, a relaxin-based compound shown to reduce fibrosis and support healthy tissue repair.

How Do Senescent (Old) Cells Make Fibrosis Worse?

Senescent cells stop dividing but remain active and release inflammatory signals known as SASP. These signals drive chronic inflammation and are linked to the progression of fibrosis. Studies show senescent cells accumulate in damaged lung and liver tissue and worsen fibrotic disease.

These cells release growth factors such as TGF-beta that activate fibroblasts and increase collagen production. This leads to excessive scar tissue and tissue stiffening.

Senescent cells also disrupt normal healing and reduce tissue regeneration. Persistent inflammation creates a cascade effect that makes fibrosis harder to resolve naturally.

FOXO4-DRI peptide targets senescent cells in laboratory studies. Animal research shows that removing these cells reduces collagen buildup and improves tissue repair.

Discover FOXO4-DRI Peptide from Peptide Works, a senolytic peptide that targets aging cells to reduce inflammation and fibrotic scarring.

What Triggers Chronic Inflammation in Damaged Tissues?

Immune cells such as mast cells release inflammatory cytokines after tissue injury. These signals include TNF-α, IL-6, and growth factors that promote inflammation and fibrosis. Environmental toxins, infections and persistent tissue damage also trigger white blood cell accumulation and prolonged inflammation. This process leads to continued tissue damage and fibrosis over time.

Studies show the relaxin-derived peptide B7-33 can reduce fibrosis in preclinical models. B7-33 activates RXFP1 receptors and promotes the expression of collagen-degrading enzymes involved in tissue remodeling.

Peptide Works supplies B7-33 for researchers studying these inflammatory mechanisms. Researchers use this peptide to understand how chronic inflammation leads to permanent scarring.

B7-33’s effectiveness depends on RXFP1 receptor signaling, which regulates tissue repair and fibrosis responses after injury.

How Do RXFP1 Receptors Control Tissue Scarring?

RXFP1 receptors sit on cell surfaces and regulate how tissues respond to damage. B7-33 binds to RXFP1 and preferentially activates pERK1/2 signaling rather than cAMP pathways.

Preclinical studies show that activation of RXFP1 by B7-33 can reduce fibrosis by decreasing collagen deposition and promoting matrix metalloproteinase-2 (MMP-2), which supports extracellular matrix breakdown.

Additional studies report that B7-33 reduces fibrosis in multiple animal models of heart and lung disease, confirming its antifibrotic activity via RXFP1 signaling pathways.

These mechanisms are used in research to examine how RXFP1 signaling regulates fibroblast activity, collagen turnover, and tissue remodeling during fibrotic progression.

How Do Cells Know Whether to Heal or Scar?

Cells use chemical signals, such as cytokines and growth factors, to decide whether to heal or form a scar. Platelets release PDGF and TGF-β after injury, which recruit fibroblasts and regulate collagen production during tissue repair.

Excessive TGF-β signaling activates fibroblasts and promotes the buildup of extracellular matrix, leading to fibrosis and scar formation. Abnormal or prolonged TGF-β activity is strongly linked to pathological scarring.

Chronic injury and inflammation keep fibroblasts active and increase collagen deposition, shifting tissues toward scarring instead of regeneration.

Mesenchymal stem cells can reduce fibrosis by regulating inflammation and improving tissue regeneration. Studies show these cells help promote regenerative healing and limit scar formation.

Can Stem Cells Fix Damaged Tissue?

Stem cells release signaling factors that regulate inflammation and cellular responses to injury. Research shows mesenchymal stem cells (MSCs) are studied for their ability to reduce inflammatory activity and reduce fibrosis by modulating immune responses and extracellular matrix processes in disease models.

Preclinical studies show that MSCs can affect fibroblast behavior, collagen deposition, and tissue remodeling, key processes in fibrosis.

Early clinical research suggests stem cell therapies are feasible and under investigation for pulmonary fibrosis, but their safety and effectiveness are not yet fully established.

Because fibrosis involves persistent inflammation and abnormal tissue remodeling, stem cells are used in research to examine how inflammation and fibrotic processes change in response to stem cell signaling in damaged tissues.

How Does Lung Scarring Affect Your Breathing?

Lung scarring creates thick, stiff tissue that reduces lung expansion and makes breathing harder. Scarred lungs lose elasticity, limiting the ability to take deep breaths and reducing lung capacity.

Fibrosis also thickens the tissue around air sacs, making it harder for oxygen to move into the bloodstream. Reduced oxygen transfer leads to shortness of breath, fatigue, and reduced activity tolerance.

As scarring progresses, lung function declines and breathing becomes more difficult. Severe fibrosis can lead to advanced breathing problems and reduced oxygen levels.

Because scar tissue limits oxygen exchange and lung flexibility, research focuses on treatments that reduce fibrosis and improve breathing capacity in damaged lungs.

How Does Bronchogen Peptide Support Lung Repair and Airway Function?

Bronchogen is a short tetrapeptide studied for tissue-specific effects in bronchial epithelial cells. Research shows it stimulates expression of differentiation factors in these cells, which are required for maintaining normal airway structure and function.

In preclinical lung models, Bronchogen peptide reduced structural damage in airway tissue by reversing epithelial remodeling, including goblet cell hyperplasia and inflammatory infiltration, and restoring ciliated epithelial cells.

Studies also report that Bronchogen modulates inflammatory activity and improves the structural and functional state of bronchial epithelium.

Because the bronchial epithelium regulates airway defense and repair, these effects are used in research to study how restoring epithelial structure may support lung recovery after injury.

Check out Bronchogen Peptide from Peptide Works, a peptide studied in models of bronchial epithelial function and airway tissue response.

The Future of Peptides in Fibrosis Research

The future of peptide research focuses on mechanisms that may reduce fibrosis through multiple cellular pathways. Researchers are studying compounds such as B7-33, FOXO4-DRI, and Bronchogen peptide to better understand inflammation control, fibrotic signaling, and bronchial epithelial function.

These research tools help investigate extracellular matrix breakdown, fibroblast activity, cellular proliferation, and airway-related cellular processes. Studies also examine how peptides may inhibit pro-fibrotic pathways while supporting normal tissue structure and regulation.

Future research may explore peptide combinations to improve anti-fibrotic effects and tissue remodeling outcomes. These compounds remain research tools and are used to better understand fibrotic mechanisms and cellular responses involved in tissue biology.

All peptides and compounds mentioned are strictly for research purposes only and not for human use.

References

(1) Alam F, Gaspari TA, Kemp-Harper BK, Low E, et al The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy. Biomed Pharmacother. 2023 Apr;160:114370.

(2) Bhuiyan S, Shen M, Chelvaretnam S, Tan AY, et al. Assessment of renal fibrosis and anti-fibrotic agents using a novel diagnostic and stain-free second-harmonic generation platform. FASEB J. 2021 May;35(5):e21595.

(3) Han X, Yuan T, Zhang J, Shi Y, et al. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. J Cell Mol Med. 2022 Jun;26(11):3269-3280. doi: 10.1111/jcmm.17333. Epub 2022 May 5. Erratum in: J Cell Mol Med. 2024 Aug;28(16):e18502. 

(4) Ye X, Li J, Liu Z, Sun X, Wei D, Song L, Wu C. Peptide mediated therapy in fibrosis: Mechanisms, advances and prospects. Biomed Pharmacother. 2023 Jan;157:113978. 

(5) Titova ON, Kuzubova NA, Lebedeva ES, Preobrazhenskaya TN, Surkova EA, Dvorakovskaya IV. [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY]. Ross Fiziol Zh Im I M Sechenova. 2017 Feb;103(2):201-8.